Table 1.
Patient characteristics (n = 12)
| Age, median (range, years) | 64·5 (44–78) |
|---|---|
| Gender, n (%) | |
| Male | 10 (83·3) |
| Female | 2 (16·7) |
| Histology, n (%) | |
| Clear cell | 7 (58·3) |
| Papillary | 2 (16·7) |
| Unknown | 3 (25·0) |
| T stage, n (%) | |
| T1a | 1 (8·3) |
| T1b | 1 (8·3) |
| T2a | 1 (8·3) |
| T2b | 1 (8·3) |
| T3a | 7 (58·3) |
| T3b | 0 (0) |
| T3c | 0 (0) |
| T4 | 1 (8·3) |
| N stage, n (%) | |
| N0 | 9 |
| N1 | 1 (8·3) |
| N2 | 2 (75·0) |
| M stage, n (%) | |
| M0 | 0 (0) |
| M1 | 12 (100) |
| Site of metastasis, n (%) | |
| Lung | 6 (50·0) |
| Liver | 3 (25·0) |
| Bone | 2 (16·7) |
| Lymph node | 5 (41·7) |
| Peritoneum | 1 (8·3) |
TNM (tumour node metastasis) stage was determined with reference to Unio Internationalis Contra Cancrum (UICC). The clinical stage of all patients was stage IV.